AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05932732
Drug: ReGen-GF
RxNorm normalized name: Regener-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
Trial: NCT05113940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as tablets; Q8H or Q12H over 14 days
Trial: NCT05789992
Drug: Low Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (Random:0-3ug/ml)
Trial: NCT05789992
Drug: Heigh Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (Random:3-5ug/ml)
Trial: NCT04147949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules taken twice a day for 14 days
Trial: NCT05510986
Drug: Fentanyl group
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
Trial: NCT05229965
Drug: Paracetamol Codeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
Trial: NCT04751500
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving medications to contract the womb to pass the retained pregnancy tissue
Trial: NCT05079438
Drug: Dendrobium Huoshanense Suppository
RxNorm normalized name: Dendrobium moniliforme whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7g rectal administration per day for 5 weeks
Trial: NCT05899725
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
Trial: NCT05593432
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Trial: NCT04990739
Drug: MTB-9655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime.
Trial: NCT06090474
Drug: NDC-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NDC-002B and NDC-002C
Trial: NCT05771428
Drug: Placebo for ABBV-552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06004661
Drug: AAA617
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously once every cycles (1 cycle = 6 weeks)
Trial: NCT04714372
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
Trial: NCT06098014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare with Thalidomide
Trial: NCT05698186
Drug: Thero2-01S22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Trial: NCT05698186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Trial: NCT05698186
Drug: Thero2-01S22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
Trial: NCT05459597
Drug: antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
Trial: NCT05819229
Drug: Oral antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days.
Trial: NCT00002103
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00226642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04210570
Drug: Chemical granulate absorber
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
Trial: NCT05223101
Drug: Drug: Micardis 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of telmisartan 80 mg
Trial: NCT04516681
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5g/kg/day, D1-3, every 2 weeks
Trial: NCT04516681
Drug: FOLFOX Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
Trial: NCT00000899
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05615467
Drug: LY3556050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05578404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to Vit D
Trial: NCT06417281
Drug: 5 Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3±1 hours before anesthesia, participants will take 5-ALA orally at a dosage of 20 mg/kg, followed by fluorescence-guided resection of malignant glioma.
Trial: NCT04654689
Drug: G04CB02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G04CB02, in a single daily dose for 4 months
Trial: NCT05558410
Drug: HB/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05558410
Drug: Placebo (matched to VX-548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-548 for oral administration.
Trial: NCT05558410
Drug: Placebo (matched to HB/APAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to HB/APAP for oral administration.
Trial: NCT04779645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-Week, once weekly subcutaneous injection with placebo
Trial: NCT05159193
Drug: pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
Trial: NCT05159193
Drug: cyclophosphamide (C)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
Trial: NCT04558502
Drug: Minocycline hydrochloride capsule
RxNorm normalized name: Minocycline Hydrochloride Capsules
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT04558502
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic for H. pylori eradication
Trial: NCT05647993
Drug: Azithromycin Injection [Zithromax]
RxNorm normalized name: azithromycin Injection [Zithromax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
Trial: NCT05367661
Drug: CHK336
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05367661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05374343
Drug: pyroglutamate rongliflozin capsules
RxNorm normalized name: pyroglutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one 50mg capsule orally (by mouth) on Day 1
Trial: NCT04691661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03528681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
Trial: NCT04689308
Drug: MH048
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
Trial: NCT04727515
Drug: fentanyl 2µg/kg intravenously and maintained with isoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
Trial: NCT06598943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered
Trial: NCT06574204
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The researchers injected 30 units of erythromycin into the inner right wrist of the subjects, which is a liquid dosage form.
Trial: NCT06574204
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The researchers injected 30 units of azithromycin into the inner right wrist of the subjects, which is a liquid dosage form.
Trial: NCT06590870
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.
Trial: NCT06590870
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
Trial: NCT05809687
Drug: DKP21102_B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT05809687
Drug: DKP21102_A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Control
Trial: NCT04711837
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 for induction of general anesthesia.
Trial: NCT05035498
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Trial: NCT04629729
Drug: FT819
RxNorm normalized name: Furmonertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Interventional Therapy
Trial: NCT04629729
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT03883893
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen will be given in the OR.
Trial: NCT00117078
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05356793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH-1 vehicle minus active components eyedrop
Trial: NCT04377945
Drug: Part 1, JM-010 component Group A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM-010 component Group A
Trial: NCT04377945
Drug: Part 1, JM-010 component Group B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM-010 component Group B
Trial: NCT04377945
Drug: Part 1, JM-010 component Group C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM-010 component Group C
Trial: NCT04377945
Drug: Part 1, Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group
Trial: NCT04377945
Drug: Part 2, JM-010 combination Group A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM-010 combination Group A
Trial: NCT04377945
Drug: Part 2, JM-010 combination Group B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JM-010 combination Group B
Trial: NCT04377945
Drug: Part 2, Placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group
Trial: NCT04150458
Drug: 18F-fluorocholine PET/CT.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-fluorocholine positron emission tomography / computed tomography
Trial: NCT05559814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal flushing of placebo solution through the scope during scope withdrawal
Trial: NCT05902728
Drug: HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
Trial: NCT05902728
Drug: HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
Trial: NCT05902728
Drug: HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg
Trial: NCT05076422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06001619
Drug: Prostate hyperplasia medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
Trial: NCT06001619
Drug: LhRH-antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
Trial: NCT05282004
Drug: SOK583A1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
Trial: NCT05347069
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin administered
Trial: NCT04898907
Drug: ANG-3777 (Therapeutic Dose)
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
Trial: NCT06528314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT06670196
Drug: SKB264
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg/kg, intravenous (IV) infusion
Trial: NCT05347485
Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
Trial: NCT04898907
Drug: ANG-3777 (Supra-therapeutic Dose)
RxNorm normalized name: Supra Sulfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
Trial: NCT04898907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention will receive normal saline, IV, Fasted
Trial: NCT01543750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04919564
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
Trial: NCT05629962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
Trial: NCT05503953
Drug: AGSAVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptitation
Trial: NCT06676891
Drug: RZ-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intracerebral injection of RZ-001, Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
Trial: NCT04734873
Drug: Placebo + SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo plus standard of care
Trial: NCT06334133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05681728
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
Trial: NCT04685148
Drug: Transdermal patch estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
Trial: NCT04685148
Drug: Transdermal patch placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
Trial: NCT05269628
Drug: Placebo CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
Trial: NCT05269628
Drug: Placebo THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be taken twice per day in the same schedule and manner as active dronabinol.
Trial: NCT06676319
Drug: Short-Acting Beta Agonists (SABA)
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Trial: NCT06676319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
Trial: NCT05063370
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will not receive Levosimendan and will receive standard care according to the institution protocol
Trial: NCT06205030
Drug: anti-diabetic herbal drug
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the volunteers directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received NOSHIN SHAHD drug 20 ml three times per day after food. at the end of the six week. then, the sample collection will be done to review all the tests of the end stage of receiving the drug.
Trial: NCT06503679
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT05398445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a placebo subcutaneously.
Trial: NCT06253871
Drug: IAM1363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, immediate release capsules of IAM1363
Trial: NCT05312645
Drug: Diclofenac 1% Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams topically four times daily for 2 weeks to posterior cervical spine
Trial: NCT06488781
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 milligrams intravenously once and cefazolin 2 grams intravenously every 8 hours for up to three doses
Trial: NCT06488781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given in place of other two active drugs
Trial: NCT05430867
Drug: GV-971 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GV-971 450mg twice a day
Trial: NCT00497120
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06604325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.